Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Overall MarketRank^™

2.77 out of 5 stars

Medical Sector

2nd out of 2,042 stocks

Pharmaceutical Preparations Industry

1st out of 770 stocks

4.5 Analyst's Opinion

Consensus Rating
Horizon Therapeutics Public has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $111.36, Horizon Therapeutics Public has a forecasted upside of 26.7% from its current price of $87.93.
Amount of Analyst Coverage
Horizon Therapeutics Public has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.3 Community Rank

Outperform Votes
Horizon Therapeutics Public has received 864 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Horizon Therapeutics Public has received 438 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Horizon Therapeutics Public has received 66.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics Public and other stocks. Vote “Outperform” if you believe HZNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Horizon Therapeutics Public does not currently pay a dividend.
Dividend Growth
Horizon Therapeutics Public does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Horizon Therapeutics Public insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,558,283.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Horizon Therapeutics Public is held by insiders.
Percentage Held by Institutions
88.59% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4 Earnings and Valuation

Earnings Growth
Earnings for Horizon Therapeutics Public are expected to grow by 33.96% in the coming year, from $3.21 to $4.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Horizon Therapeutics Public is 24.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of Horizon Therapeutics Public is 24.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.18.
Price to Earnings Growth Ratio
Horizon Therapeutics Public has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Horizon Therapeutics Public has a P/B Ratio of 7.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public or view top-rated stocks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Horizon Therapeutics Public.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.07 by $0.04. The biopharmaceutical company had revenue of $342.41 million for the quarter, compared to analysts' expectations of $389.51 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 25.66% and a net margin of 43.55%. Horizon Therapeutics Public's revenue for the quarter was down 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.40 earnings per share.
View Horizon Therapeutics Public's earnings history.

How has Horizon Therapeutics Public's stock price been impacted by COVID-19?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HZNP shares have increased by 188.2% and is now trading at $87.93.
View which stocks have been most impacted by COVID-19.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $2.75 billion-$2.85 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for HZNP?

11 brokerages have issued 12 month target prices for Horizon Therapeutics Public's stock. Their forecasts range from $90.00 to $125.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $111.36 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:

Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 54, Pay $5.48M)
Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 56, Pay $1.88M)
Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 67, Pay $1.71M)
Dr. Jeffrey W. Sherman M.D., F.A.C.P., Exec. VP & Chief Medical Officer (Age 66, Pay $1.55M)
Mr. Andy Pasternak, Exec. VP & Chief Strategy Officer (Age 50, Pay $1.79M)
Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 56)
Ms. Tina E. Ventura, Sr. VP of Investor Relations
Mr. Brian K. Beeler, Exec. VP & Gen. Counsel (Age 48)
Mr. Timothy Ayers, Chief Compliance Officer & VP
Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 46)

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

Some companies that are related to Horizon Therapeutics Public include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of HZNP's competitors.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.86%), Standard Life Aberdeen plc (0.85%), Congress Asset Management Co. MA (0.78%), Victory Capital Management Inc. (0.63%), Scout Investments Inc. (0.47%) and Oak Ridge Investments LLC (0.47%). Company insiders that own Horizon Therapeutics Public stock include Barry Moze, Brian K Beeler, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani.
View institutional ownership trends for Horizon Therapeutics Public.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Congress Asset Management Co. MA, Virginia Retirement Systems ET AL, Los Angeles Capital Management LLC, AMI Asset Management Corp, IFP Advisors Inc, C WorldWide Group Holding A S, and Emerald Advisers LLC. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Barry Moze, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani.
View insider buying and selling activity for Horizon Therapeutics Public or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Oak Ridge Investments LLC, BNP Paribas Arbitrage SA, Victory Capital Management Inc., Alliancebernstein L.P., Standard Life Aberdeen plc, Scout Investments Inc., and Fifth Third Bancorp.
View insider buying and selling activity for Horizon Therapeutics Public or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $87.93.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $19.70 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,395 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 5/9/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Horizon Therapeutics Public Stock Forecast, Price & News

Adding

Adding

Adding Horizon Therapeutics Public Limited

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About Horizon Therapeutics Public

MarketRank™

Overall MarketRank™